Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma

We report 5-year follow-up of a multicenter phase 2 study of lenalidomide plus rituximab (LR) as initial treatment of mantle cell lymphoma (MCL). The regimen includes induction and maintenance with the LR doublet. Treatment was continuous until progression, with optional discontinuation after 3 year...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Ruan, Jia, Martin, Peter, Christos, Paul, Cerchietti, Leandro, Tam, Wayne, Shah, Bijal, Schuster, Stephen J., Rodriguez, Amelyn, Hyman, David, Calvo-Vidal, Maria Nieves, Smith, Sonali M., Svoboda, Jakub, Furman, Richard R., Coleman, Morton, Leonard, John P.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2018
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6634960/
https://ncbi.nlm.nih.gov/pubmed/30181173
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2018-07-859769
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados